Abstract
Frailty may modify the risk versus benefit of various therapeutic interventions in heart failure. In this study, the authors performed a post hoc analysis of the DAPA-HF trial to examine the effica... Visual Dapagliflozin and Frailty in HFrEF. Frailty may modify the risk versus benefit of various therapeutic interventions in heart failure. In this study, the authors performed a post hoc... Background: Frailty may modify the risk−benefit profile of certain treatments, and frail patients may have reduced tolerance to treatments. Objective: To investigate the efficacy of dapagliflozin a...

This publication has 34 references indexed in Scilit: